New Targeted Gum Disease Treatment Developed That Preserves Helpful Mouth Bacteria
Researchers at the University of Florida College of Dentistry and the Fraunhofer Institute for Cell Therapy and Immunology announced new targeted treatments for gum disease in 2024. According to study leaders, the therapies selectively inhibit the harmful bacterium Porphyromonas gingivalis while preserving beneficial oral bacteria, aiming to prevent infection without disrupting the mouth’s healthy microbial balance.
The University of Florida College of Dentistry and the Fraunhofer Institute for Cell Therapy and Immunology jointly developed these treatments based on new insights into the behavior of Porphyromonas gingivalis, a bacterium recognized as the keystone pathogen responsible for aggressive gum disease. According to Jorge Frias-Lopez, Ph.D., an oral biologist leading the UF study, the bacteria possess a genetic “brake” mechanism that controls their virulence. Frias-Lopez said that even small amounts of P. gingivalis can orchestrate this shift by influencing other bacteria, making it a critical target for treatment.
Locking this brake silences P. gingivalis, preventing it from manipulating the entire microbial community in the mouth, which otherwise shifts a healthy oral environment toward disease.
Traditional gum disease therapies, including plaque scraping, tissue removal, and antibiotics, indiscriminately kill bacteria, harming beneficial microbes that maintain oral health, according to the UF researchers. While newer regenerative treatments help restore gum tissue, they lack the precision to stop infection without disrupting the mouth’s microbial balance. The new approach aims to inhibit P. gingivalis selectively, preserving helpful bacteria and preventing the recurrence of dysbiosis, or microbial imbalance, that often follows conventional treatment.
At the Fraunhofer Institute’s Halle branch, researchers identified a compound called guanidinoethylbenzylamino imidazopyridine acetate that selectively blocks P. gingivalis growth without affecting other oral bacteria. Stephan Schilling, head of molecular drug biochemistry and therapy development at Fraunhofer IZI, explained that the substance inhibits the pathogen’s toxic effects, allowing beneficial bacteria to occupy ecological niches in the mouth. Schilling said this mechanism works in harmony with the natural microbial community to rebuild and stabilize oral health.
The compound is formulated into a care gel developed by the PerioTrap spin-off company, which is applied after professional dental cleanings to block pathogenic bacteria and maintain gum suppleness. Fraunhofer officials said ongoing development includes an herbal mouthwash expected to launch by July 1, 2025, and toothpaste formulations that selectively inhibit periodontal pathogens such as P. gingivalis. The technology is also being expanded into additional oral care products beyond gels and mouthwashes.
P. gingivalis thrives in inflamed gum tissue, gaining an advantage after conventional treatments eliminate beneficial bacteria, according to Fraunhofer researchers. Current antiseptic mouthwashes, including those containing alcohol or chlorhexidine, kill both harmful and beneficial bacteria, often leading to the return of microbial imbalance and disease. The new compound does not kill P. gingivalis outright but prevents it from exerting toxic effects, allowing slower-growing beneficial bacteria to stabilize the oral microbiome over time. Schilling noted that the substance disrupts bacterial communication, or “chatter,” tipping the balance toward a healthy microbial community.
The concept of targeting oral pathogens while preserving beneficial bacteria has historical roots. According to research records, the probiotic approach to oral health began in 1985 when Hillman and colleagues isolated Streptococcus strains that inhibited P. gingivalis through hydrogen peroxide production. Replacement therapy, which involves competitive exclusion of pathogens by beneficial microbes, has been foundational since 1987. Probiotics have been shown to reduce oral pathogens, inhibit dental caries, and lower bacteria that cause halitosis. They are particularly effective against anaerobic bacteria involved in periodontitis, such as P. gingivalis and Tannerella forsythia, according to a 2023 review of immunomodulatory therapies for oral cancer prevention.
The UF and Fraunhofer teams emphasized that preserving the structural integrity of the oral microbiome by avoiding indiscriminate bacterial killing supports long-term oral health and enables regenerative therapies without microbiome disruption. According to Frias-Lopez and Schilling, this targeted approach could represent a significant advance in managing periodontal disease by neutralizing the keystone pathogen’s influence rather than eradicating the entire microbial community. Further clinical testing and product development are underway to bring these therapies into broader dental care markets.
